Understanding the immune response in COVID-19 patients
Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19
This study is trying to see how the immune response works in people with different severities of COVID-19 and if certain genetic factors affect how well it fights the virus.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | rituximab, chemotherapy |
| Locations | 1 site (Lyon) |
| Trial ID | NCT06703034 on ClinicalTrials.gov |
What this trial studies
This study investigates the type I interferon (IFN-I) response in individuals who have experienced varying severities of COVID-19. It focuses on how genetic mutations and autoantibodies may affect the effectiveness of the IFN-I pathway, which is crucial for the immune system's defense against viral infections. Participants will undergo biological sampling to assess their immune responses and identify potential defects in the IFN-I pathway. The findings could provide insights into the prognosis and treatment of COVID-19.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have previously participated in specific COVID-19 related studies and weigh at least 50 kg.
Not a fit: Patients currently experiencing infection symptoms or those with significant immunosuppression will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of COVID-19, particularly for patients with severe forms of the disease.
How similar studies have performed: Other studies have identified defects in the IFN-I response in severe COVID-19 cases, suggesting that this approach has been explored with some success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant aged at least 18 years * Previously included in the COVID-ser or NOSO-COR IMMUNO study as well as in the RNIPH study (Research Not Involving Human Persons) named MIR-COVID * Weight of 50 kg or more Exclusion Criteria: * Current infection symptoms * Immunosuppression defined by: bone marrow transplant within the past 24 months, chemotherapy within the past 6 months, HIV infection with CD4 \<200/mm³ or \<15%, corticosteroid therapy for more than 2 weeks with a daily dose over 10 mg of prednisolone equivalent, immunosuppressive treatment administered within the previous 3 months (6 months for rituximab), aplasia, asplenia, or splenectomy * Pregnant, parturient, or breastfeeding woman * Person deprived of liberty by judicial or administrative decision * Person receiving psychiatric care * Person admitted to a health or social institution for purposes other than research * Person under guardianship or curators * Person not affiliated with a social security scheme or similar coverage * Patient participating in another ongoing interventional research study at inclusion"
Where this trial is running
Lyon
- Hospices Civils de Lyon - Hôpital de la Croix-Rousse — Lyon, France (Recruiting)
Study contacts
- Study coordinator: Jean-Christophe RICHARD, Pr
- Email: j-christophe.richard@chu-lyon.fr
- Phone: +33472011762
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.